4.04
Precedente Chiudi:
$4.27
Aprire:
$4.26
Volume 24 ore:
53,942
Relative Volume:
0.54
Capitalizzazione di mercato:
$229.35M
Reddito:
-
Utile/perdita netta:
$-66.86M
Rapporto P/E:
-3.3667
EPS:
-1.2
Flusso di cassa netto:
$-58.82M
1 W Prestazione:
+0.50%
1M Prestazione:
+1.76%
6M Prestazione:
-18.71%
1 anno Prestazione:
-15.48%
Design Therapeutics Inc Stock (DSGN) Company Profile
Nome
Design Therapeutics Inc
Settore
Industria
Telefono
858-293-4900
Indirizzo
6005 HIDDEN VALLEY ROAD, CARLSBAD
Confronta DSGN con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
![]()
DSGN
Design Therapeutics Inc
|
4.04 | 241.27M | 0 | -66.86M | -58.82M | -1.20 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
472.27 | 120.73B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
564.64 | 61.80B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
328.00 | 42.46B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
591.74 | 35.22B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
296.46 | 31.99B | 3.81B | -644.79M | -669.77M | -6.24 |
Design Therapeutics Inc Stock (DSGN) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2024-05-07 | Aggiornamento | Piper Sandler | Neutral → Overweight |
2023-11-14 | Downgrade | Piper Sandler | Overweight → Neutral |
2023-08-15 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
2023-08-15 | Downgrade | SVB Securities | Outperform → Market Perform |
2023-08-15 | Downgrade | Wedbush | Outperform → Neutral |
2023-05-04 | Aggiornamento | Goldman | Sell → Neutral |
2022-06-10 | Iniziato | Wedbush | Outperform |
2022-05-02 | Iniziato | RBC Capital Mkts | Outperform |
2022-01-19 | Iniziato | Goldman | Sell |
2021-04-20 | Iniziato | Goldman | Neutral |
2021-04-20 | Iniziato | Piper Sandler | Overweight |
2021-04-20 | Iniziato | SVB Leerink | Outperform |
Mostra tutto
Design Therapeutics Inc Borsa (DSGN) Ultime notizie
How high can Design Therapeutics Inc. stock price go in 2025Breakthrough stock performance - jammulinksnews.com
What drives Design Therapeutics Inc. stock pricePhenomenal returns - PrintWeekIndia
Design Therapeutics Inc. Stock Analysis and ForecastFree Stock Market Real-Time Monitoring - jammulinksnews.com
What analysts say about Design Therapeutics Inc. stockPhenomenal capital gains - jammulinksnews.com
Is Design Therapeutics Inc. a good long term investmentBreakthrough financial growth - jammulinksnews.com
Is ECASH(ethereumcash) a Good InvestmentLow Volatility High Yield Stocks - Newser
What drives AORT stock priceExceptional market positioning - PrintWeekIndia
Is Laureate Education Inc. a good long term investmentPhenomenal capital gains - Autocar Professional
Best Indian Stocks for Portfolio Protection AI Recommended Market StrategiesPhenomenal wealth increase - jammulinksnews.com
What analysts say about SBXC WS stockOutstanding capital appreciation - jammulinksnews.com
Is Design Therapeutics Inc. stock a growth or value playFree Membership Group - Newser
Design Therapeutics (NASDAQ:DSGN) Stock Price Down 3.1% – Should You Sell? - Defense World
Why Design Therapeutics Inc. stock attracts strong analyst attentionDefensive Stock Picks with Upside - beatles.ru
Why Synaptogenix Inc. stock attracts strong analyst attentionSecure Your Capital Strategy - Newser
What makes Design Therapeutics Inc. stock price move sharplyDaily Breakout Picks - Newser
How SIMAU stock performs during market volatilityFast Moving Stock Alerts - Newser
Why Sionna Therapeutics Inc. stock attracts strong analyst attentionFree VIP Investment Strategies - Newser
How Design Therapeutics Inc. stock performs during market volatilityElite Stock Shortlist - Newser
High-Potential Biotech Penny Stocks in 2025: ProKidney and Design Therapeutics Lead the Way - AInvest
Penny Stocks To Watch In July 2025 - simplywall.st
Maze Therapeutics Soars 11.68% on Wedbush's Outperform Rating - AInvest
BioVie Highlights Patient-Centric Design of SUNRISE-PD - GlobeNewswire
FDA Boosts CERo's Revolutionary T Cell Therapy with Orphan Drug Status for Deadly Blood Cancer - Stock Titan
PRDS(brise paradise) Future OutlookFree Group Entry - Newser
Design Therapeutics Confirms Directors at Annual Meeting - TipRanks
Design Therapeutics Inc Azioni (DSGN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):